CRT Raises Price Target On Valeant Pharmaceuticals, 'Well Positioned For Growth'
January 09, 2015 at 10:17 AM EST
CRT Capital raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $170 to $180 and maintained a Buy ...
